DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Esophageal Cancer” report has been added to ResearchAndMarkets.com’s
offering.
This Market Spotlight report covers the esophageal cancer market,
comprising key marketed and pipeline drugs, patent information, a
10-year disease incidence forecast, and licensing and acquisition deals.
Key Takeaways:
-
The report estimates that in 2017, there were 488,800 incident cases
of esophageal cancer worldwide, and expects that number to increase to
534,700 incident cases by 2026. -
Incidence is higher in males compared to females, and is highest in
the Asia region. Photofrin, a two-step therapy that involves the
injection of the photoactive drug followed by drug activation using
laser therapy, is the only FDA-approved drug for esophageal cancer. -
The majority of industry-sponsored drugs in active clinical
development for esophageal cancer are in Phase II. Therapies in
development for esophageal cancer focus on a wide variety of targets.
The majority of pipeline drugs in mid-to-late stage development are
administered intravenously, with three drugs being tested in oral
formulations. -
The only high-impact upcoming event in the esophageal cancer space is
topline Phase III trial results for Opdivo. The overall likelihood of
approval of a Phase I solid tumor asset is 5.7%, and the average
probability a drug advances from Phase III is 39.4%. Drugs, on
average, take 9.5 years from Phase I to approval, compared to 9.2
years in the overall oncology space. -
There have been 10 licensing and asset acquisition deals involving
esophageal cancer drugs during 2014-19. The $1,456m drug development
collaboration agreement signed in 2015 between Eli Lilly and Innovent
Biologics to support the development and potential commercialization
of at least three cancer treatments was the largest deal. -
The distribution of clinical trials across Phase I-IV indicates that
the vast majority of trials for esophageal cancer have been in the
early and mid-phases of development, with 91% of trials in Phase I-II,
and only 9% in Phase III-IV. -
The US has a substantial lead in the number of esophageal cancer
clinical trials globally. The UK leads the major EU markets, while
Japan has the top spot in Asia. -
Clinical trial activity in the esophageal cancer space is dominated by
completed trials. Sanofi has the highest number of completed clinical
trials for esophageal cancer, with 89 trials. -
Roche and Sanofi lead industry sponsors with the highest number of
clinical trials for esophageal cancer.
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
TREATMENT
Surgery
Radiation therapy
Endoscopic therapy
Chemotherapy
Targeted therapy
Immunotherapy
EPIDEMIOLOGY
MARKETED DRUGS
PIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
Keytruda for Esophageal Cancer (January 14, 2019)
Opdivo for Esophageal Cancer (January 9, 2019)
Keytruda for Esophageal Cancer (November 14, 2018)
Keytruda for Esophageal Cancer (June 3, 2018)
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
Merck’s Keytruda Shows Utility In Subset Of Esophageal Cancer
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
PARENT PATENTS
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
BIBLIOGRAPHY
Prescription information
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/y5j2rg
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs